Clinically, an increasing burden of peripheral-blood-circulating CD14+HLA-DRlo/neg cells correlates with poor patient outcomes across multiple tumor types, including NSCLC [10,11,14,15,16,17,18,19]. This evidence concerns the gene CD14 and neoplasm.